Accéder au contenu
Merck

Simple Determination of Plasma Ponatinib Concentration Using HPLC.

Biological & pharmaceutical bulletin (2017-12-08)
Takeo Yasu, Kenji Momo, Shunsuke Kobayashi, Seiichirou Kuroda, Arinobu Tojo
RÉSUMÉ

Ponatinib, a novel tyrosine kinase inhibitor marketed in 2016, is a key drug used for treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. This study aimed to develop a simple method for determining plasma ponatinib concentration. The analysis required extraction of a 400-µL sample of plasma and precipitation of proteins using an Oasis HLB cartridge. Ponatinib and bosutinib, which is used as an internal standard, were separated by HPLC using a mobile phase of acetonitrile : 0.037 mol/L KH